Inogen (INGN) Earnings Date & Reports

Key Takeaways

• Inogen (INGN) is scheduled to report second quarter 2026 financial results after the market closes on Thursday, August 6, 2026.
• Company-issued revenue guidance for Q2 2026 stands at $94 million to $97 million, representing approximately 3.5% year-over-year growth at the midpoint.
• Wall Street consensus estimates project a GAAP loss of approximately $0.17 per share on revenue of roughly $95.2 million, according to data from multiple analyst surveys.
• International revenue remains a bright spot, having surged 18% year-over-year in Q1 2026, while U.S. direct-to-consumer sales declined 5% during the same period.
• Management has reaffirmed full-year 2026 revenue guidance of $366 million to $373 million and signaled that Q2 and Q3 should represent the strongest quarters for profitability this year.
• The stock trades near $6.31 with a 52-week range of $5.34 to $9.13, while analysts maintain a consensus Strong Buy rating and an average 12-month price target of approximately $12.67.

Earnings Context and Why It Matters

Inogen's upcoming Q2 2026 report arrives at a pivotal moment for the medical device company. The portable oxygen concentrator maker is navigating a multi-year turnaround under CEO Kevin Smith, with encouraging international growth offset by persistent softness in its U.S. direct-to-consumer (DTC) channel. Investors are watching closely to see whether Inogen can sustain its top-line recovery while making measurable progress toward profitability. In Q1 2026, the company posted revenue of $85.11 million that beat consensus estimates, yet its GAAP loss of $0.30 per share missed expectations by $0.06 — a reminder that revenue growth alone has not yet translated to bottom-line performance. With new product launches including the Voxi 5 stationary oxygen concentrator and Aurora CPAP (continuous positive airway pressure) masks beginning to scale, this quarter offers an important checkpoint on the company's broader transformation strategy.

Earnings Expectations

For the second quarter of 2026, Inogen's management has guided for reported revenue in the range of $94 million to $97 million, which at the midpoint implies approximately 3.5% growth relative to Q2 2025 revenue of $92.28 million. Consensus analyst estimates, based on surveys from multiple research firms, point to revenue of approximately $95.2 million and a GAAP earnings per share loss of roughly $0.17. On an adjusted basis, some analysts project a narrower loss of around $0.06 per share.

These expectations reflect a mixed backdrop. In the prior quarter, Inogen delivered a revenue beat driven largely by 18% year-over-year international revenue growth, which reached $37.7 million. However, U.S. sales declined 5% to $34.7 million, weighed down by lower rental revenue and a challenging DTC environment. Adjusted gross margin held relatively steady at 44.7%, up 30 basis points year-over-year, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) came in at negative $1.4 million.

For context, Inogen has beaten consensus revenue estimates in several recent quarters, but EPS has been more uneven. In Q4 2025, the company posted a GAAP loss of $0.26 per share — notably better than the $0.36 loss analysts had forecast. The stock's reaction to earnings has historically been mixed, with modest post-release swings reflecting investor uncertainty around the pace of the turnaround.

AI Screener

For investors seeking to identify earnings-driven opportunities beyond individual stock analysis, Tickeron's AI Screener offers a powerful discovery tool. The AI Screener is an AI-powered stock and ETF filtering platform that enables traders and investors to scan thousands of securities using customizable criteria such as technical patterns, fundamental metrics, volatility profiles, industry classification, market capitalization, and AI-driven trading signals. Whether you are searching for breakout candidates, stocks exhibiting specific chart patterns, or names poised for earnings-related volatility, the screener helps streamline the research process far more efficiently than manual screening. Explore the AI Screener to uncover new trade ideas and monitor how stocks like Inogen stack up against peers across the medical device landscape.

Market Reaction and Investor Sentiment

Sentiment around Inogen heading into the Q2 2026 report is cautiously optimistic but far from euphoric. The stock has been trading near the lower end of its 52-week range, changing hands at approximately $6.31 as of late July 2026 — well below the average analyst price target of $12.67. This wide gap between the current share price and Wall Street's valuation suggests that the market remains skeptical about the speed and durability of Inogen's turnaround, despite the consensus Strong Buy rating from covering analysts.

One notable risk factor is the elevated short interest in the stock, which stood at roughly 1.05 million shares as of mid-July, representing approximately 5.2 days to cover. A better-than-expected print on both revenue and profitability could trigger a short squeeze, while a miss — particularly on the bottom line or forward guidance — would likely reinforce bearish positioning. The divergence between strong international performance and domestic weakness also creates a binary setup: investors will be parsing whether international growth can finally offset U.S. headwinds or whether channel mix deterioration continues to pressure margins.

Forward Outlook and Key Factors to Monitor

Looking beyond the August 6 release, several factors will shape Inogen's trajectory for the remainder of 2026 and into 2027.

New Product Ramp. The commercial rollout of the Voxi 5 stationary oxygen concentrator and Aurora CPAP masks represents a significant growth catalyst. Management has indicated that these products are expected to scale meaningfully in the second half of 2026. Investors should listen for any updated commentary on early adoption trends, customer feedback, and revenue contribution from these newer offerings during the earnings call.

U.S. Channel Stabilization. The persistent decline in domestic DTC and rental revenue remains the most visible headwind. Inogen has been restructuring its sales approach and investing in its business-to-business (B2B) channel, which has shown relative strength. Signs that U.S. revenue contraction is moderating — or that B2B gains are accelerating — would be viewed favorably by the market.

Margin Trajectory. While management has reiterated a commitment to full-year adjusted EBITDA improvement, the path to sustainable profitability depends on gross margin expansion and operating expense discipline. Q1 adjusted R&D (research and development) spending rose to $4.1 million from $3.2 million a year earlier as the company invests in clinical evidence and product development. Investors will want to see that this spending is yielding tangible commercial results without excessive dilution to near-term earnings.

Balance Sheet Strength. With approximately $111.5 million in cash and equivalents and no debt as of Q1 2026, Inogen has ample runway to fund its turnaround. The company also repurchased roughly 298,000 shares for approximately $1.9 million during Q1, signaling management's confidence in the long-term value proposition. Any update to capital allocation plans — including the pace of buybacks — will also be of interest.

Full-Year Guidance. Inogen has maintained its 2026 revenue outlook of $366 million to $373 million, and the Q2 report will be a critical test of whether that range remains achievable. A reaffirmation — or even a modest raise — would reinforce the narrative of a steady turnaround. Conversely, any downward revision would likely reignite concerns about the durability of the recovery.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations